Quoin Pharmaceuticals, Ltd.
QRX003
Netherton Syndrome
Resolved
7days ago
Phase 2 readout · Jun 30, 2026
What's at stake
Phase 2 trial results for QRX003 in Netherton Syndrome are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“Quoin anticipates reporting topline data in the second half of 2026.”